Single and Double Lung Transplantation Have Equivalent Survival for Idiopathic Pulmonary Fibrosis

Ranganath, Neel K.; Malas, Jad; Phillips, Katherine G.; Lesko, Melissa; Smith, Deane E.; Angel, Luis F.; Lonze, Bonnie E.; Kon, Zachary N.

doi:10.1016/j.athoracsur.2019.06.090

Cited by 26 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, one might suggest that patients with IPF undergoing single LTx might benefit from continuation to attenuate fibrosis progression in the native lung [1]. Conversely, recent studies reported no differences in survival between bilateral LTx and single LTx for patients with IPF, and therefore there might be no added value from antifibrotics [49][50][51]. The first results of a single-centre randomised controlled trial investigating continuation of nintedanib after single LTx in IPF subjects are expected in December 2021 (NCT03562416).…”

Section: Antifibrotics After Single Ltxmentioning

confidence: 99%

Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review

Bos¹,

Sadeleer

Vanstapel

et al. 2021

Eur Respir Rev

View full text Add to dashboard Cite

This review aims to provide an overview of pre-transplant antifibrotic therapy on peri-transplant outcomes and to address the possible role of antifibrotics in lung transplant recipients with chronic lung allograft dysfunction.Lung transplantation is an established treatment modality for patients with various end-stage lung diseases, of which idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases are growing indications. Theoretically, widespread use of antifibrotics prior to lung transplantation may increase the risk of bronchial anastomotic complications and impaired wound healing.Long-term graft and patient survival are still hampered by development of chronic lung allograft dysfunction, on which antifibrotics may have a beneficial impact.Antifibrotics until the moment of lung transplantation proved to be safe, without increasing peri-transplant complications. Currently, best practice is to continue antifibrotics until time of transplantation. In a large multicentre randomised trial, pirfenidone did not appear to have a beneficial effect on lung function decline in established bronchiolitis obliterans syndrome. The results of antifibrotic therapy in restrictive allograft syndrome are eagerly awaited, but nonrandomised data from small case reports/series are promising.

show abstract

Section: Antifibrotics After Single Ltxmentioning

confidence: 99%

Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review

Bos¹,

Sadeleer

Vanstapel

et al. 2021

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…So far, the surgical technique seems to be safer compared with the percutaneous approach since airway opening is short and controlled with the cuffed tube placed caudally to the trachea opening. Some modifications to the well-known percutaneous techniques have been proposed to minimise the risk related to COVID-19 infection 20 . These uncertainties are reflected in Figure 5, where differences in terms of technique and postintubation day are revealed.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic on Italian Otolaryngology Units: a nationwide study

Mannelli

Ralli

Bonali

et al. 2020

Acta Otorhinolaryngol Ital

View full text Add to dashboard Cite

Objective. The aim of this study was to provide an accurate picture of the changes which have occurred during the COVID-19 pandemic, and the contributions given by Italian Otolaryngology Units. Methods. A 29-item questionnaire was completed and returned by 154 Otorhinolaryngology Units across Italy that investigated geographic distribution, the main changes which occurred in workload management and in clinical and surgical activities and screening procedures for COVID-19 in healthcare personnel and patients. Results. Nearly half of the Otolaryngology Units that responded to the questionnaire were merged with other units, while 22% were converted into COVID-19 units or temporarily closed. A reduction of 8.55% in the number of team members was reported, and about 50% of the units applied uniform work shifts for all staff. Elective activities were uniformly stopped or delayed, passing from 30,295 (pre-COVID data) to 5,684 (COVID data) weekly procedures, with a mean decrease of 81.24% (p < 0.001). Conclusions. Most of the elective otolaryngology activities were suspended during the pandemic; the only procedures were for oncology and emergency patients. Italian Otolaryngologists have demonstrated a high availability to collaborate with non-surgical colleagues.

show abstract

“…After detailed evaluation, 10 studies were excluded for lacking sufficient data to extract (n = 2), or the survival outcome evaluated in other diseases other than IPF (n = 8). Ultimately, 16 studies with 17,872 IPF cases distributed in five countries were included in this meta-analysis [4][5][6][7][17][18][19][20][21][22][23][24][25][26][27][28] (Fig 1). These studies were published between 2005 and 2019, among which six were single-center studies, while the other ten were multi-center studies.…”

Section: Baseline Characteristics Of Eligible Studiesmentioning

confidence: 99%

“…Most recently, a large study with 4134 recipients demonstrated that DLT was associated with better graft survival than SLT in patients with IPF [4]. Later, numerous studies suggested that the use of SLT versus DLT in IPF did not correspond to significantly different survival [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Liu

Wang

2020

PLoS ONE

View full text Add to dashboard Cite

Lung transplantation remains the only curative treatment for end-stage lung disease, conferring a better survival for some IPF patients, but whether they should receive double lung transplantation (DLT) or single lung transplantation (SLT) is still controversial. The aim of this study was to determine which type of lung transplantation was more effective and relatively safe in IPF patients by meta-analysis. Methods Publications comparing overall survival (OS) or other perioperative characteristics between IPF patients undergoing SLT and DLT were selected from electronic databases. The hazard ratios (HRs) were abstracted or calculated to evaluate the survival outcome. Odds ratios (ORs) or mean differences (MDs) were used to compare the causes of death or perioperative parameters. A random-effect model was used to combine data. Heterogeneity was quantified by means of an I 2 with 95% confidence interval (95% CI). The publication bias was estimated using the Eggers test with Begg's funnel plots. Results 16 studies with 17,872 IPF cases who met the inclusion criteria were included in this metaanalysis. SLT was associated with declined post-transplant FEV1% (

show abstract

Single and Double Lung Transplantation Have Equivalent Survival for Idiopathic Pulmonary Fibrosis

Cited by 26 publications

References 14 publications

Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review

Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review

Impact of COVID-19 pandemic on Italian Otolaryngology Units: a nationwide study

Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Contact Info

Product

Resources

About